Where the science of peptides becomes clear.
An education-first resource for clinicians, researchers, athletes, and curious readers exploring the modern peptide landscape — from GLP-1 agonists transforming obesity care to the regenerative and longevity peptides driving today's research conversations.
Browse by category
Featured peptides
Semaglutide
Long-acting GLP-1 receptor agonist with FDA approvals across type 2 diabetes, obesity, and cardiovascular risk reduction.
Type 2 diabetes, Obesity and weight management
Tirzepatide
Dual GIP/GLP-1 receptor agonist — the first incretin co-agonist to reach the market.
Type 2 diabetes, Obesity and weight management
Retatrutide
Triple GIP / GLP-1 / glucagon receptor agonist — the next-generation incretin candidate.
Obesity (Phase 3), Type 2 diabetes (Phase 3)
BPC-157
A pentadecapeptide derived from a gastric protein, widely studied in animal models for tissue protection and recovery.
Tendon and ligament recovery research, Gut protection and inflammatory bowel models
PT-141
Melanocortin-receptor agonist acting centrally on the desire-and-arousal pathway.
Hypoactive sexual desire disorder (HSDD) — FDA-approved, Erectile dysfunction (off-label and prior development)
Tesamorelin
Stabilized GHRH analog, FDA-approved for HIV-associated lipodystrophy
HIV-associated visceral adipose tissue (VAT) excess — FDA-approved, Investigational: non-alcoholic fatty liver disease
GHK-Cu
Glycyl-histidyl-lysine in complex with copper (II)
Cosmetic skin care (established), Wound healing (evidence)
MOTS-c
A 16-amino-acid peptide encoded within the mitochondrial genome — central to a new class of "mitokines."
Metabolic health and insulin sensitivity research, Exercise capacity and skeletal muscle adaptation
Established science
Peptides with multiple Phase 3 trials and regulatory approvals — including semaglutide, tirzepatide, tesamorelin, and PT-141 — represent the strongest end of the evidence spectrum.
Start with semaglutide →Active research areas
BPC-157, TB-500, MOTS-c, epitalon and others sit in the active-research zone — promising mechanisms with growing animal data and emerging human trials.
See BPC-157 →Regulatory landscape
The FDA's evolving stance on compounded peptides shapes what's available and where. We summarize the current rules and what they mean for clinicians and researchers.
Read the context →In-depth reading
Semaglutide vs tirzepatide vs retatrutide
A head-to-head walkthrough of mechanism, trial weight-loss outcomes, side effects, and access for the three leading incretin therapies.
Read articlePreserving lean mass on GLP-1s
What DEXA substudies in STEP and SURMOUNT show, and which mitigation strategies have meaningful supporting evidence.
Read articleThe BPC-157 tendon question
Sorting the substantial preclinical data from the persistent claim that BPC-157 has been clinically validated for tendon healing.
Read articleLatest GLP-1 research
SELECT, FLOW, STEP-HFpEF, SURMOUNT-OSA, TRIUMPH — what the most recent landmark trials are showing.
Read articleHow we weigh evidence
Every claim on this site is anchored to a tier of evidence. We are clear about what is established, what is promising, and what is still developing — without dismissing reader interest or the genuine signals in early-stage research.